ImmuCell Corporation (ICCC)
NASDAQ: ICCC · Real-Time Price · USD
6.57
+0.02 (0.31%)
Feb 27, 2026, 4:00 PM EST - Market closed
ImmuCell Employees
As of December 31, 2024, ImmuCell had 75 total employees, including 77 full-time and 7 part-time employees. The number of employees decreased by 4 or -5.06% compared to the previous year.
Employees
75
Change (1Y)
-4
Growth (1Y)
-5.06%
Revenue / Employee
$330,587
Profits / Employee
$27,663
Market Cap
59.43M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| TScan Therapeutics | 148 |
| Metagenomi Therapeutics | 124 |
| InflaRx | 74 |
| Mereo BioPharma Group | 36 |
| Q32 Bio | 26 |
| NeurAxis | 21 |
| Instil Bio | 14 |
| Spruce Biosciences | 9 |
ICCC News
- 10 days ago - ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2025 - GlobeNewsWire
- 7 weeks ago - ImmuCell Corporation (ICCC) Q4 2025 Sales/Trading Call Transcript - Seeking Alpha
- 7 weeks ago - ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 and Full Year of 2025 - GlobeNewsWire
- 7 weeks ago - ImmuCell to Conduct Conference Call with Investors to Discuss Strategic Change in Focus - GlobeNewsWire
- 2 months ago - ImmuCell Announces Strategic Focus on First Defense® After Receiving an FDA Incomplete Letter for Re-Tain® - GlobeNewsWire
- 3 months ago - ImmuCell Corporation (ICCC) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2025 - GlobeNewsWire
- 4 months ago - ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2025 - GlobeNewsWire